Anticholinergic therapy for overactive bladder: a nicotinic modality?

Area of Science:

• Urology
• Pharmacology
• Neuroscience

Background:

• Current Overactive Bladder (OAB) treatments primarily target muscarinic acetylcholine receptors, often resulting in limited efficacy and side effects.
• Nicotinic acetylcholine receptor (nAChR) subtypes are present in the bladder urothelium and afferent nerves, playing a role in urgency signaling and voiding.
• Chronic overstimulation of bladder nAChRs by acetylcholine presents a therapeutic target for OAB.

Purpose of the Study:

• To propose and hypothesize a novel therapeutic strategy for OAB targeting nAChRs.
• To investigate the potential of an orally administered, nAChR-selective inhibitor with renal elimination for OAB treatment.

Main Methods:

• Hypothesized administration of an orally administered, nAChR-selective inhibitor.
• Focus on extensive renal elimination to achieve higher local bladder concentrations.
• Aiming for reduced systemic exposure compared to existing OAB therapies.

Main Results:

• Anticipated higher local concentrations of the nAChR inhibitor within the bladder.
• Expected lower systemic exposure, potentially reducing off-target side effects.
• A targeted approach to OAB treatment with a potentially improved side effect profile.

Conclusions:

• Targeting nAChRs in the bladder offers a promising alternative to antimuscarinic therapies for OAB.
• An orally administered nAChR-selective inhibitor with renal elimination may provide a novel, targeted OAB treatment.
• This approach holds the potential for improved efficacy and a more favorable side effect profile in managing OAB.